XIAMEN AMOYTOP BIOTECH CO., LTD.

Xiamen Amoytop Biotech Co., Ltd. is an innovative biopharmaceutical company and a listed company on the Science and Technology Innovation Board (SSE STAR Market) in China, specializing in R&D, manufacturing and marketing of regular and long-acting recombinant protein drugs. Focusing on the R&D of immune-related cytokine medicines, Amoytop Biotech is committed to becoming a leader in solving cytokine medicine-based systemic immune problems, providing better solutions for major diseases (such as viral hepatitis, malignant tumors) and immunotherapy. Looking into the future, Amoytop Biotech is especially focusing on CHB (chronic hepatitis B) treatment and will keep advancing the clinical research progress of multiple ongoing pipeline programs aiming to achieve breakthroughs in the clinical cure of CHB. Targeting major diseases and immunotherapy fields, Amoytop Biotech has built an innovation platform covering the expression, long-acting modification and industrialization of various protein drugs, and owned the innovation ability in fundamental research, pilot-scale research, clinical study and industrialization research. Now, Amoytop Biotech has established national post-doctoral workstation and national-local joint research center, and has been awarded as a national innovation-oriented enterprise that has advantages in national intellectual property. Keeping the global market in mind, Amoytop Biotech spares no effort to explore international market based on the domestic market. Up to now, Amoytop Biotech has marketed its products in many countries. Through technical innovation, scientific management and product industrialization, Amoytop Biotech aims to gradually become a leading international biopharmaceutical company in China.